Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Abivax S.A.. (2/11/16). "Press Release: Abivax to Participate in the Upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London". Paris.

Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Organisation Abivax S.A. (Euronext Paris: ABVX)
  Group Abivax (Group)
  Organisation 2 RBC Capital Markets, LLC
Products Product RBC Capital Markets Global Healthcare Conference 2016 New York
  Product 2 Credit Suisse Global Healthcare Conference 2016 London
Index terms Index term Abivax–RBC Capital Markets: investor conference, 201602 supply service Abivax participates in RBC Capital Markets Healthcare Conference
  Index term 2 Abivax–Credit Suisse: investor conference, 201603 supply service Abivax particpates in Credit Suisse Healthcare Conference in London
Persons Person Ehrlich, Hartmut J. (Abivax 201410 CEO before Baxter BioScience 200712 VP Global RnD)
  Person 2 Chevallier, Alain (Truffle Capital 201701– before Abivax CFO)

ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will participate in the RBC Capital Markets 2016 Healthcare Conference in New York on February 23rd and 24th, and in the Credit Suisse Healthcare Conference in London on March 1st and 2nd.

At the RBC Capital Markets 2016 Healthcare conference, Prof. Ehrlich is scheduled to participate in a fireside chat with RBCCM healthcare analyst Douglas Miehm at 8:30 AM (EST) on February 23rd. This conversation will be webcast, and will be available on ABIVAX’s website. Additionally, Prof. Ehrlich and ABIVAX’s CFO, Alain Chevallier, will conduct one-on-one meetings with interested investors over the course of the conference.

At the Credit Suisse Healthcare conference in London, Prof. Ehrlich and Mr. Chevallier will meet with investors in one-on-one meetings over the course of the conference.

ABIVAX ( is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.

Follow us on Twitter @ABIVAX_


Investor relations
Raquel Lizarraga, +33 1 53 83 09 63


Citigate Dewe Rogerson
Lucie Larguier, +33 1 53 32 84 75


Press relations
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / + 33 1 44 54 36 64


LifeSci Advisors
Chris Maggos, +41 79 367 6254

Record changed: 2017-07-02


Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Abivax (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px

» top